Interleukin-17 and cystic fibrosis lung disease.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Role of IL-17 family cytokines in the progression of IPF from inflammation to fibrosis.Military Medical Research · 2022
   Review
2. IL-17A impairs host tolerance during airway chronic infection by Pseudomonas aeruginosa.Scientific reports · 2016
   Article
3. A High Level of Soluble CD40L Is Associated with P. aeruginosa Infection in Patients with Cystic Fibrosis.PloS one · 2016
   Article
4. Adult non-cystic fibrosis bronchiectasis is characterised by airway luminal Th17 pathway activation.PloS one · 2015
   Article
5. T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis.PloS one · 2014
   Article

Corrections and comments

• Comment on
  The Th17 pathway in cystic fibrosis lung disease.2011

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as